Big Pharma Buys Rivals To Price Gouge Patients

On Feb. 10, Valeant Pharmaceuticals International Inc. bought the rights to a pair of lifesaving heart drugs. The same day, their list prices rose by 525 and 212. Neither of the drugs, Nitropress or Isuprel, was improved as a result of costly investment in lab work and human testing, Valeant said. Nor was manufacture of the medicines shifted to an expensive new plant. The big change: the drugs Read More At: